Incretin Atlas › Trials › HRS9531-201 (NCT05881837)
HRS9531-201 (NCT05881837)
Ribupatide (HRS9531) · obesity
Design
- Molecule(s)
- Ribupatide (HRS9531)
- Population
- obesity
- Phase
- 2
- Participants
- 249
- Duration
- 24 weeks
- Registry
- NCT05881837
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.0 mg | obesity china | 24 | 249 | — | −5.4 % vs −0.1 % Δ −5.3 pp | — | 2.0 vs 2.0 | — | 14.3 vs 8.2 | 6.1 vs 2.0 | — | — | congress |
| 3.0 mg | obesity china | 24 | 249 | — | −13.4 % vs −0.1 % Δ −13.3 pp | — | 2.0 vs 2.0 | — | 27.5 vs 8.2 | 19.6 vs 2.0 | — | — | congress |
| 4.5 mg | obesity china | 24 | 249 | — | −14.0 % vs −0.1 % Δ −13.9 pp | — | 0.0 vs 2.0 | — | 32.0 vs 8.2 | 20.0 vs 2.0 | — | — | congress |
| 6.0 mg | obesity china | 24 | 249 | — | −16.8 % vs −0.1 % Δ −16.7 pp | — | 0.0 vs 2.0 | — | 32.7 vs 8.2 | 28.6 vs 2.0 | — | — | congress |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (16)
- 1.0 mg · weight_tp · abstract
in body weight was -5.4% (95% CI -7.3% to -3.5%), -13.4% (-15.2% to -
- 1.0 mg · nausea · abstract
Nausea 7 (14.3) 14 (27.5) 16 (32.0) 16 (32.7) 4 (8.2)
- 1.0 mg · vomiting · abstract
Vomiting 3 (6.1) 10 (19.6) 10 (20.0) 14 (28.6) 1 (2.0)
- 1.0 mg · ae_dc · Table 3 (Adverse events), columns 1.0/3.0/4.5/6.0 mg/placebo
1 (2.0) 1 (2.0) 0 0 1 (2.0)
- 3.0 mg · weight_tp · abstract
in body weight was -5.4% (95% CI -7.3% to -3.5%), -13.4% (-15.2% to -
- 3.0 mg · nausea · abstract
Nausea 7 (14.3) 14 (27.5) 16 (32.0) 16 (32.7) 4 (8.2)
- 3.0 mg · vomiting · abstract
Vomiting 3 (6.1) 10 (19.6) 10 (20.0) 14 (28.6) 1 (2.0)
- 3.0 mg · ae_dc · Table 3 (Adverse events), columns 1.0/3.0/4.5/6.0 mg/placebo
1 (2.0) 1 (2.0) 0 0 1 (2.0)
- 4.5 mg · weight_tp · abstract
11.5%), -14.0% (-15.9% to -12.1%), and -16.8% (-18.8% to -14.9%) in the
- 4.5 mg · nausea · abstract
Nausea 7 (14.3) 14 (27.5) 16 (32.0) 16 (32.7) 4 (8.2)
- 4.5 mg · vomiting · abstract
Vomiting 3 (6.1) 10 (19.6) 10 (20.0) 14 (28.6) 1 (2.0)
- 4.5 mg · ae_dc · Table 3 (Adverse events), columns 1.0/3.0/4.5/6.0 mg/placebo
1 (2.0) 1 (2.0) 0 0 1 (2.0)
- 6.0 mg · weight_tp · abstract
11.5%), -14.0% (-15.9% to -12.1%), and -16.8% (-18.8% to -14.9%) in the
- 6.0 mg · nausea · abstract
Nausea 7 (14.3) 14 (27.5) 16 (32.0) 16 (32.7) 4 (8.2)
- 6.0 mg · vomiting · abstract
Vomiting 3 (6.1) 10 (19.6) 10 (20.0) 14 (28.6) 1 (2.0)
- 6.0 mg · ae_dc · Table 3 (Adverse events), columns 1.0/3.0/4.5/6.0 mg/placebo
1 (2.0) 1 (2.0) 0 0 1 (2.0)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: HRS9531-201 (NCT05881837). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs9531-201/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.